BYSI
Price
$0.64Alerts
Change
+$0.06 (+10.34%)
Updated
Nov 11 closing price
Capitalization
25.74M
Earnings call today
Intraday BUY SELL Signals
RCUS
Price
$18.77Alerts
Change
+$0.10 (+0.54%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
2.33B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BYSI vs RCUS

BYSI vs RCUS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BYSI vs. RCUS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BYSI is a Hold and RCUS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BYSI with price predictions
Nov 10, 2026

BYSI in downward trend: price dove below 50-day moving average on November 05, 2026

BYSI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 42 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BYSI moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 18 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 44 cases where BYSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.

The 10-day moving average for BYSI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BYSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

BYSI broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BYSI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BYSI as a result. In 73 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for BYSI just turned positive on October 30, 2026. Looking at past instances where BYSI's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.

Following a +55.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BYSI advanced for three days, in 174 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.724) is normal, around the industry mean (3.498). P/E Ratio (-3.682) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (31.056) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. BYSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BYSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RCUS with price predictions
Nov 10, 2026

RCUS's RSI Oscillator recovers from oversold territory

The RSI Oscillator for RCUS moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 30 of the 34 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 62 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on RCUS as a result. In 76 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for RCUS just turned positive on November 04, 2026. Looking at past instances where RCUS's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.

Following a +7.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 215 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for RCUS moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for RCUS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.016) is normal, around the industry mean (3.498). P/E Ratio (-4.640) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. RCUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
BYSI vs RCUS: Fundamental Ratings
BYSI
RCUS
OUTLOOK RATING
1..100
4232
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6578
P/E GROWTH RATING
1..100
1013
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BYSI's Valuation (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for RCUS (60). This means that BYSI’s stock grew somewhat faster than RCUS’s over the last 12 months.

BYSI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RCUS (100). This means that BYSI’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as BYSI (99). This means that RCUS’s stock grew similarly to BYSI’s over the last 12 months.

BYSI's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as RCUS (78). This means that BYSI’s stock grew similarly to RCUS’s over the last 12 months.

BYSI's P/E Growth Rating (10) in the Pharmaceuticals Major industry is in the same range as RCUS (13). This means that BYSI’s stock grew similarly to RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BYSIRCUS
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BYSI: $0.58 vs. RCUS: $18.67)
Brand notoriety: BYSI and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BYSI: 30% vs. RCUS: 54%
Market capitalization -- BYSI: $25.74M vs. RCUS: $2.33B
BYSI [@Biotechnology] is valued at $25.74M. RCUS’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BYSI’s FA Score shows that 2 FA rating(s) are green while RCUS’s FA Score has 1 green FA rating(s).

  • BYSI’s FA Score: 2 green, 3 red.
  • RCUS’s FA Score: 1 green, 4 red.
According to our system of comparison, BYSI is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BYSI’s TA Score shows that 3 TA indicator(s) are bullish while RCUS’s TA Score has 6 bullish TA indicator(s).

  • BYSI’s TA Score: 3 bullish, 7 bearish.
  • RCUS’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than BYSI.

Price Growth

BYSI (@Biotechnology) experienced а -6.65% price change this week, while RCUS (@Biotechnology) price change was -1.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

BYSI is expected to report earnings on Nov 11, 2026.

RCUS is expected to report earnings on Mar 02, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BYSI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BYSI has been loosely correlated with GOSS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BYSI jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BYSI
1D Price
Change %
BYSI100%
-6.05%
GOSS - BYSI
38%
Loosely correlated
+5.97%
CYTK - BYSI
37%
Loosely correlated
+1.89%
VNDA - BYSI
33%
Poorly correlated
-0.24%
TAOX - BYSI
31%
Poorly correlated
-5.15%
RCUS - BYSI
31%
Poorly correlated
-1.48%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-1.48%
VIR - RCUS
50%
Loosely correlated
-3.63%
DYN - RCUS
47%
Loosely correlated
-3.76%
KURA - RCUS
46%
Loosely correlated
N/A
RCKT - RCUS
44%
Loosely correlated
-3.16%
NRIX - RCUS
44%
Loosely correlated
-1.61%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HCOW25.740.13
+0.49%
Amplify COWS Covered Call ETF (HCOW)
QXQ30.07-0.20
-0.65%
SGI Enhanced Nasdaq 100 ETF (QXQ)
OIA5.80-0.08
-1.36%
INVESCO Municipal Income OPPORTUNITIES TRUST
IHAK68.00-1.01
-1.46%
iShares Cybersecurity & Tech ETF (IHAK)
ETNG8.81-0.19
-2.11%
Leverage Shares 2X Long ETN Daily ETF (ETNG)